presatovir
Small moleculeexperimental
Presatovir (GS-5806) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown promising results in Phase II clinical trials. — Wikipedia
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01756482)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
- Fusion glycoprotein F0INHIBITOR
Fusion glycoprotein F0 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1- Mol. weight
- 532.07 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPresatovir ↗
- ChEMBLCHEMBL3410450 ↗
Also known as
- gs-5806
- gs-5806
- gs-5806
- presatovir
- presatovir
- presatovir
- presatovir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02534350 | Phase 2 | Dec 31, 2015 | Gilead Sciences |
| NCT02254421 | Phase 2 | Jan 31, 2015 | Gilead Sciences |
| NCT02254408 | Phase 2 | Jan 1, 2015 | Gilead Sciences |
| NCT02135614 | Phase 2 | Jun 9, 2014 | Gilead Sciences |
| NCT01797419 | Phase 1 | May 1, 2013 | Gilead Sciences, University of Queensland |
| NCT01801293 | Phase 1 | Mar 1, 2013 | Gilead Sciences |
| NCT01756482 | Phase 2 | Nov 1, 2012 | Gilead Sciences, hVIVO Services Limited |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 7 | 7 | 2 | 2012 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2012 |
| University of Queensland | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1